[go: up one dir, main page]

MX2008015976A - Tratamiento topico para enfermedades de superficie ocular. - Google Patents

Tratamiento topico para enfermedades de superficie ocular.

Info

Publication number
MX2008015976A
MX2008015976A MX2008015976A MX2008015976A MX2008015976A MX 2008015976 A MX2008015976 A MX 2008015976A MX 2008015976 A MX2008015976 A MX 2008015976A MX 2008015976 A MX2008015976 A MX 2008015976A MX 2008015976 A MX2008015976 A MX 2008015976A
Authority
MX
Mexico
Prior art keywords
eye
diseases
topical treatment
eye surface
agent
Prior art date
Application number
MX2008015976A
Other languages
English (en)
Inventor
Andreas Reiff
Scott M Hampton
Original Assignee
Therakine Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therakine Ltd filed Critical Therakine Ltd
Publication of MX2008015976A publication Critical patent/MX2008015976A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe una solución ocular tópica para el tratamiento de enfermedades córneas, esclerales, o conjunctivales. En una modalidad de la presente invención, la solución ocular comprende un fluido basado en solución salina, y una cantidad eficaz de por lo menos un compuesto o agente terapéutico, en donde cuando por lo menos una gota de la solución ocular se aplica a la superficie de un ojo, el compuesto o agente terapéutico se libera en la córnea y conjunctiva del ojo.
MX2008015976A 2006-06-12 2006-06-12 Tratamiento topico para enfermedades de superficie ocular. MX2008015976A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/022747 WO2007145618A1 (en) 2006-06-12 2006-06-12 Topical treatment for diseases of eye surface

Publications (1)

Publication Number Publication Date
MX2008015976A true MX2008015976A (es) 2009-04-14

Family

ID=38832025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008015976A MX2008015976A (es) 2006-06-12 2006-06-12 Tratamiento topico para enfermedades de superficie ocular.

Country Status (8)

Country Link
US (1) US20100028328A1 (es)
EP (1) EP2026822A4 (es)
JP (1) JP2009539977A (es)
CN (1) CN101489569A (es)
BR (1) BRPI0621761A2 (es)
CA (1) CA2654565A1 (es)
MX (1) MX2008015976A (es)
WO (1) WO2007145618A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009025763A2 (en) 2007-08-16 2009-02-26 Schepens Eye Research Institute Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
CA3069576A1 (en) 2008-01-09 2009-07-16 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
US10117906B2 (en) * 2009-01-09 2018-11-06 The Schepens Eye Research Institute, Inc. Methods for reducing corneal nerves damage, corneal lymphangiogenesis or immunity to corneal antigens in dry-eye associated ocular surface diseases by IL-1Ra
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
CA2806438C (en) 2010-07-29 2021-04-13 Eleven Biotherapeutics, Inc. Chimeric il-1 receptor type i agonists and antagonists
US9474715B2 (en) 2011-11-30 2016-10-25 Andreas Voigt Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
KR102236926B1 (ko) 2013-03-13 2021-04-06 세센 바이오, 아이엔씨. 안구 운반을 위한 키메릭 사이토카인 제제
CA2928626C (en) * 2013-11-14 2023-03-14 The Doshisha Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
WO2017110093A1 (ja) 2015-12-24 2017-06-29 学校法人同志社 ＴＧＦ－βシグナルに起因する障害を治療または予防するための医薬およびその応用
EP3399999A4 (en) * 2016-01-07 2020-03-11 The Schepens Eye Research Institute, Inc. THERAPEUTICS FOR IMMUNE-INFLAMMATORY DISEASES OF THE EYE
CN110227148B (zh) * 2019-07-02 2023-02-17 王雁 Cxcl14重组蛋白在制备角膜药物中的应用
CN116617405A (zh) * 2023-04-21 2023-08-22 四川大学 具有粘膜粘附性的脂质体药物载体及其制备方法和应用
US20250108141A1 (en) * 2023-09-29 2025-04-03 Unm Rainforest Innovations Topical formulations for targeted delivery of therapeutics

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830508A (en) * 1992-08-06 1998-11-03 Deo Corporation Composition for treating dry eye
JPH10330257A (ja) * 1997-06-02 1998-12-15 Senju Pharmaceut Co Ltd 眼局所用サイトカイン産生抑制剤
EP1054900A4 (en) * 1998-02-13 2004-12-22 Human Genome Sciences Inc THERAPEUTIC USE OF THE KERATINOCTENT GROWTH FACTOR-2
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
US6864232B1 (en) * 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
US7063857B1 (en) * 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US20030007971A1 (en) * 2000-01-31 2003-01-09 Hideaki Hara Remedies for ophthalmic diseases
TWI287987B (en) * 2000-08-14 2007-10-11 Senju Pharma Co Cytokine inhibitor
ATE516820T1 (de) * 2000-09-29 2011-08-15 Schering Corp Pegyliertes interleukin 10
EP1364949A4 (en) * 2001-02-02 2005-11-23 Takeda Pharmaceutical JNK INHIBITOR
US6534059B2 (en) * 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US20040062768A1 (en) * 2001-06-05 2004-04-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
WO2006042101A1 (en) * 2004-10-06 2006-04-20 The Government Of The United States As Represented By The Secretary Of Health And Human Services Method for treating active uveitis
BRPI0518582A2 (pt) * 2004-11-24 2008-11-25 Therakine Corp implante para liberaÇço de medicamento intra-ocular

Also Published As

Publication number Publication date
JP2009539977A (ja) 2009-11-19
BRPI0621761A2 (pt) 2011-12-20
US20100028328A1 (en) 2010-02-04
EP2026822A1 (en) 2009-02-25
CA2654565A1 (en) 2007-12-21
CN101489569A (zh) 2009-07-22
EP2026822A4 (en) 2012-07-04
WO2007145618A1 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
MX2008015976A (es) Tratamiento topico para enfermedades de superficie ocular.
WO2008070185A3 (en) Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds
NZ588938A (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
WO2013030679A3 (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
MX2010003774A (es) Formulaciones oftalmicas acuosas.
WO2008070726A3 (en) Treatment for dry eye
WO2006066103A3 (en) Ophthalmic implant for treatment of glaucoma
WO2007149832A3 (en) Punctal plugs for the delivery of active agents
MX364441B (es) Composiciones de povidona-yodo oftalmicas no irritantes.
WO2007104541A3 (en) Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2007087061A3 (en) Glaucoma treatment device
WO2007070866A3 (en) Control of intraocular pressure using alk5 modulation agents
WO2007095618A3 (en) Benzo-fused heterocycle sulfamide derivatives for the treatment of migraine
WO2008140052A1 (ja) ロピニロール又はその塩を有効成分として含有する後眼部疾患の予防又は治療剤
WO2006122249A3 (en) Use of plasmin for preventing of reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
CY1108651T1 (el) Προληπτικος ή θεραπευτικος παραγων για γλαυκωμα
WO2009111418A3 (en) Ketorolac tromethamine compositions for treating or preventing ocular pain
WO2004066979A3 (en) Sustained release device and method for ocular delivery of adrenergic agents
CA2582316A1 (en) Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
WO2005020917A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2005087210A3 (en) Prevention of retinopathy by inhibition of the visual cycle

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal